Review



human coronary artery smcs (hcasmcs)  (Lonza)


Bioz Verified Symbol Lonza is a verified supplier
Bioz Manufacturer Symbol Lonza manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90

    Structured Review

    Lonza human coronary artery smcs (hcasmcs)
    Human Coronary Artery Smcs (Hcasmcs), supplied by Lonza, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+coronary+artery+smcs/human+coronary+artery+smcs++hcasmcs+/pm40266881-203-0-8
    Average 90 stars, based on 1 article reviews
    human coronary artery smcs (hcasmcs) - by Bioz Stars, 2026-09
    90/100 stars

    Images

    Related Articles

    Cell Culture:

    Article Title: A multiscale computational model of arterial growth and remodeling including Notch signaling.
    Article Snippet: .. Briefly, human coronary artery SMCs (Lonza) were cultured for a minimum of 7 days, according to the manufacturer’s protocol, in human vascular muscle cell basal medium (Gibco) supplemented with either 1 3 5% smooth muscle growth supplement (Gibco) to obtain synthetic SMCs or 1% smooth muscle differentiation supplement (Gibco) to obtain contractile SMCs. ..

    Article Title: A multiscale computational model of arterial growth and remodeling including Notch signaling
    Article Snippet: Briefly, human coronary artery SMCs (Lonza) were cultured for a minimum of 7 days, according to the manufacturer’s protocol, in human vascular muscle cell basal medium (Gibco) supplemented with either 5% smooth muscle growth supplement (Gibco) to obtain synthetic SMCs or 1% smooth muscle differentiation supplement (Gibco) to obtain contractile SMCs. .. Briefly, human coronary artery SMCs (Lonza) were cultured for a minimum of 7 days, according to the manufacturer’s protocol, in human vascular muscle cell basal medium (Gibco) supplemented with either 5% smooth muscle growth supplement (Gibco) to obtain synthetic SMCs or 1% smooth muscle differentiation supplement (Gibco) to obtain contractile SMCs. .. Cell-culture plates were coated with 2.2 μg/cm 2 of bovine fibronectin (Thermo Fisher Scientific).

    Article Title: Inhibition of STAT3 signaling prevents vascular smooth muscle cell proliferation and neointima formation
    Article Snippet: .. Human coronary artery SMCs were purchased from Lonza (Cologne, Germany) and cultured in optimized growth medium supplemented with 5 % FCS, 0.5 ng/ml epidermal growth factor, 2 ng/ml basic fibroblast growth factor, 5 μg/ml insulin (PromoCell, Heidelberg, Germany), according to the supplier’s protocol. ..

    Article Title: Knockout of the Murine Ortholog to the Human 9p21 Coronary Artery Disease Locus Leads to SMC Proliferation, Vascular Calcification, and Advanced Atherosclerosis
    Article Snippet: .. Human coronary artery SMCs were purchased from Lonza (CC-2583) and cultured in SmBMTM Basal Medium containing SmGMTM-2 Supplement Pack (Lonza). .. Total RNA was isolated from frozen murine tissue or cultured SMCs by Trizol (Thermo Fisher), cDNA was synthesized with Multiscribe reverse transcriptase (Applied Biosystems), and quantitative reversetranscription PCR (qPCR) was performed on the ABI PRISM 7900HT with commercially available Taqman probes (Applied Biosystems).

    Article Title: Assembly of Tissue-Engineered Blood Vessels with Spatially Controlled Heterogeneities
    Article Snippet: .. Human coronary artery SMCs (Lonza) were cultured and maintained in complete SMC growth medium (SmGM-2; Lonza) containing 5% FBS, 2ng/ml fibroblast growth factor-basic, 0.5ng/ml epidermal growth factor, insulin, 30μg/ml gentamicin, and 15ng/ml amphotericin B. ..

    Expressing:

    Article Title: Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice
    Article Snippet: .. The expression of GIPR mRNA in human monocytes was far higher than in human macrophages and human coronary artery SMCs (Lonza) (Fig. ). ..



    Similar Products

    93
    ATCC primary human coronary artery smooth muscle cells smcs
    Primary Human Coronary Artery Smooth Muscle Cells Smcs, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+coronary+artery+smcs/Primary+Coronary+Artery%3B+Smooth+Muscle+Cells%3B+Normal%2C+Human/pm40481235-30-8-20
    Average 93 stars, based on 1 article reviews
    primary human coronary artery smooth muscle cells smcs - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    95
    Cell Applications Inc human coronary artery smcs
    Human Coronary Artery Smcs, supplied by Cell Applications Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+coronary+artery+smcs/Human+Coronary+Artery+Smooth+Muscle+Cells%3A+HCASMC/pmc13066215-279-0-4
    Average 95 stars, based on 1 article reviews
    human coronary artery smcs - by Bioz Stars, 2026-09
    95/100 stars
      Buy from Supplier

    90
    Thermo Fisher human coronary artery smcs
    MYOCD/SRF remodels Hippo. To understand YAP/TAZ activation in i8-SRF-KO aorta, we overlapped YAP/TAZ regulators (171 proteins) from a recent review with the differentially expressed proteins in i8-SRF-KO versus control aorta (729 proteins) to identify an overlap of 27 proteins ( A ). YAP/TAZ activators that were increased and inhibitors that were reduced (i8-SRF-KO vs. Ctrl) were highlighted with their respective protein names in black. Subsequently, 11 out of 27 changes were expected to activate YAP/TAZ whereas the remainder were expected to inhibit YAP/TAZ. Because core Hippo kinases were not recovered in our mass spectroscopy experiment, we next overlapped core Hippo constituents with a previous RNA-seq experiment (n = 4 experiments were cell were treated with either Ad-CMV-null or Ad-CMV-MYOCD) where MYOCD was overexpressed, uncovering significant increases of MOB1A , LATS1 , and LATS2 ( B ). Moreover, both SRF and MYOCD correlated with LATS2 at the mRNA level across human arteries ( C ). We therefore hypothesized that MYOCD/SRF may control the LATS2 protein level. Western blotting using lysates from control and i8-SRF-KO aortae revealed reduction of a major Lats2 band migrating at 240 kDa ( D , summarized data in E , n = 6 mice in each group) following SRF depletion. Lats1 ( D ), and Slmap (major isoform at 40 kDa, D ), included to allow for comparison with the mass spectroscopy in A , were not significantly reduced ( D and F ). HSP90, H3, and proteins remaining on the gel after transfer were included as loading controls. A Lats2 band migrating at 240 kDa, essentially eliminated by a LATS2-targeted siRNA (siLATS2c), was also detected in cultured smooth muscle cells from the <t>human</t> <t>coronary</t> artery following MYOCD transduction ( G , n = 3 culture wells). In a larger experiment, overexpression of MYOCD in human <t>SMCs</t> increased LATS2 >50-fold ( H , I , n = 6 culture wells in two separate experiments). This was associated with an increased phospho-MOB1 level ( H and J ) and an increased P-YAP over total YAP ratio ( H and K ). Taken together, this suggests that MYOCD/SRF promotes the activity of Hippo via phospho-MOB1 and LATS2 to suppress YAP/TAZ activity; consequently, deletion of SRF in the aorta is expected to release YAP/TAZ from a critical inhibitory influence from Hippo. As prior work demonstrated that YAP/TAZ are important upstream regulators of MYOCD, we propose that the effect of MYOCD/SRF on Hippo represents an inhibitory and homeostatic feedback loop as depicted schematically in L. Lats2, large tumor suppressor kinase 2; MYOCD, myocardin; SMC, smooth muscle cell; SRF, serum response factor; TAZ, WW domain containing transcription regulator 1; YAP, Yes associated transcriptional regulator.
    Human Coronary Artery Smcs, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+coronary+artery+smcs/human+coronary+artery+smcs/pmc12002835-399-0-7
    Average 90 stars, based on 1 article reviews
    human coronary artery smcs - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    95
    Cell Applications Inc vascular smooth muscle cell proliferation assay human coronary artery smcs
    MYOCD/SRF remodels Hippo. To understand YAP/TAZ activation in i8-SRF-KO aorta, we overlapped YAP/TAZ regulators (171 proteins) from a recent review with the differentially expressed proteins in i8-SRF-KO versus control aorta (729 proteins) to identify an overlap of 27 proteins ( A ). YAP/TAZ activators that were increased and inhibitors that were reduced (i8-SRF-KO vs. Ctrl) were highlighted with their respective protein names in black. Subsequently, 11 out of 27 changes were expected to activate YAP/TAZ whereas the remainder were expected to inhibit YAP/TAZ. Because core Hippo kinases were not recovered in our mass spectroscopy experiment, we next overlapped core Hippo constituents with a previous RNA-seq experiment (n = 4 experiments were cell were treated with either Ad-CMV-null or Ad-CMV-MYOCD) where MYOCD was overexpressed, uncovering significant increases of MOB1A , LATS1 , and LATS2 ( B ). Moreover, both SRF and MYOCD correlated with LATS2 at the mRNA level across human arteries ( C ). We therefore hypothesized that MYOCD/SRF may control the LATS2 protein level. Western blotting using lysates from control and i8-SRF-KO aortae revealed reduction of a major Lats2 band migrating at 240 kDa ( D , summarized data in E , n = 6 mice in each group) following SRF depletion. Lats1 ( D ), and Slmap (major isoform at 40 kDa, D ), included to allow for comparison with the mass spectroscopy in A , were not significantly reduced ( D and F ). HSP90, H3, and proteins remaining on the gel after transfer were included as loading controls. A Lats2 band migrating at 240 kDa, essentially eliminated by a LATS2-targeted siRNA (siLATS2c), was also detected in cultured smooth muscle cells from the <t>human</t> <t>coronary</t> artery following MYOCD transduction ( G , n = 3 culture wells). In a larger experiment, overexpression of MYOCD in human <t>SMCs</t> increased LATS2 >50-fold ( H , I , n = 6 culture wells in two separate experiments). This was associated with an increased phospho-MOB1 level ( H and J ) and an increased P-YAP over total YAP ratio ( H and K ). Taken together, this suggests that MYOCD/SRF promotes the activity of Hippo via phospho-MOB1 and LATS2 to suppress YAP/TAZ activity; consequently, deletion of SRF in the aorta is expected to release YAP/TAZ from a critical inhibitory influence from Hippo. As prior work demonstrated that YAP/TAZ are important upstream regulators of MYOCD, we propose that the effect of MYOCD/SRF on Hippo represents an inhibitory and homeostatic feedback loop as depicted schematically in L. Lats2, large tumor suppressor kinase 2; MYOCD, myocardin; SMC, smooth muscle cell; SRF, serum response factor; TAZ, WW domain containing transcription regulator 1; YAP, Yes associated transcriptional regulator.
    Vascular Smooth Muscle Cell Proliferation Assay Human Coronary Artery Smcs, supplied by Cell Applications Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+coronary+artery+smcs/Human+Coronary+Artery+Smooth+Muscle+Cells%3A+HCASMC/pm41644529-256-0-10
    Average 95 stars, based on 1 article reviews
    vascular smooth muscle cell proliferation assay human coronary artery smcs - by Bioz Stars, 2026-09
    95/100 stars
      Buy from Supplier

    90
    Lonza human coronary artery smcs (hcasmcs)
    MYOCD/SRF remodels Hippo. To understand YAP/TAZ activation in i8-SRF-KO aorta, we overlapped YAP/TAZ regulators (171 proteins) from a recent review with the differentially expressed proteins in i8-SRF-KO versus control aorta (729 proteins) to identify an overlap of 27 proteins ( A ). YAP/TAZ activators that were increased and inhibitors that were reduced (i8-SRF-KO vs. Ctrl) were highlighted with their respective protein names in black. Subsequently, 11 out of 27 changes were expected to activate YAP/TAZ whereas the remainder were expected to inhibit YAP/TAZ. Because core Hippo kinases were not recovered in our mass spectroscopy experiment, we next overlapped core Hippo constituents with a previous RNA-seq experiment (n = 4 experiments were cell were treated with either Ad-CMV-null or Ad-CMV-MYOCD) where MYOCD was overexpressed, uncovering significant increases of MOB1A , LATS1 , and LATS2 ( B ). Moreover, both SRF and MYOCD correlated with LATS2 at the mRNA level across human arteries ( C ). We therefore hypothesized that MYOCD/SRF may control the LATS2 protein level. Western blotting using lysates from control and i8-SRF-KO aortae revealed reduction of a major Lats2 band migrating at 240 kDa ( D , summarized data in E , n = 6 mice in each group) following SRF depletion. Lats1 ( D ), and Slmap (major isoform at 40 kDa, D ), included to allow for comparison with the mass spectroscopy in A , were not significantly reduced ( D and F ). HSP90, H3, and proteins remaining on the gel after transfer were included as loading controls. A Lats2 band migrating at 240 kDa, essentially eliminated by a LATS2-targeted siRNA (siLATS2c), was also detected in cultured smooth muscle cells from the <t>human</t> <t>coronary</t> artery following MYOCD transduction ( G , n = 3 culture wells). In a larger experiment, overexpression of MYOCD in human <t>SMCs</t> increased LATS2 >50-fold ( H , I , n = 6 culture wells in two separate experiments). This was associated with an increased phospho-MOB1 level ( H and J ) and an increased P-YAP over total YAP ratio ( H and K ). Taken together, this suggests that MYOCD/SRF promotes the activity of Hippo via phospho-MOB1 and LATS2 to suppress YAP/TAZ activity; consequently, deletion of SRF in the aorta is expected to release YAP/TAZ from a critical inhibitory influence from Hippo. As prior work demonstrated that YAP/TAZ are important upstream regulators of MYOCD, we propose that the effect of MYOCD/SRF on Hippo represents an inhibitory and homeostatic feedback loop as depicted schematically in L. Lats2, large tumor suppressor kinase 2; MYOCD, myocardin; SMC, smooth muscle cell; SRF, serum response factor; TAZ, WW domain containing transcription regulator 1; YAP, Yes associated transcriptional regulator.
    Human Coronary Artery Smcs (Hcasmcs), supplied by Lonza, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+coronary+artery+smcs/human+coronary+artery+smcs++hcasmcs+/pm40266881-203-0-8
    Average 90 stars, based on 1 article reviews
    human coronary artery smcs (hcasmcs) - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    90
    Thermo Fisher human coronary artery smooth muscle cells (smcs)
    MYOCD/SRF remodels Hippo. To understand YAP/TAZ activation in i8-SRF-KO aorta, we overlapped YAP/TAZ regulators (171 proteins) from a recent review with the differentially expressed proteins in i8-SRF-KO versus control aorta (729 proteins) to identify an overlap of 27 proteins ( A ). YAP/TAZ activators that were increased and inhibitors that were reduced (i8-SRF-KO vs. Ctrl) were highlighted with their respective protein names in black. Subsequently, 11 out of 27 changes were expected to activate YAP/TAZ whereas the remainder were expected to inhibit YAP/TAZ. Because core Hippo kinases were not recovered in our mass spectroscopy experiment, we next overlapped core Hippo constituents with a previous RNA-seq experiment (n = 4 experiments were cell were treated with either Ad-CMV-null or Ad-CMV-MYOCD) where MYOCD was overexpressed, uncovering significant increases of MOB1A , LATS1 , and LATS2 ( B ). Moreover, both SRF and MYOCD correlated with LATS2 at the mRNA level across human arteries ( C ). We therefore hypothesized that MYOCD/SRF may control the LATS2 protein level. Western blotting using lysates from control and i8-SRF-KO aortae revealed reduction of a major Lats2 band migrating at 240 kDa ( D , summarized data in E , n = 6 mice in each group) following SRF depletion. Lats1 ( D ), and Slmap (major isoform at 40 kDa, D ), included to allow for comparison with the mass spectroscopy in A , were not significantly reduced ( D and F ). HSP90, H3, and proteins remaining on the gel after transfer were included as loading controls. A Lats2 band migrating at 240 kDa, essentially eliminated by a LATS2-targeted siRNA (siLATS2c), was also detected in cultured smooth muscle cells from the <t>human</t> <t>coronary</t> artery following MYOCD transduction ( G , n = 3 culture wells). In a larger experiment, overexpression of MYOCD in human <t>SMCs</t> increased LATS2 >50-fold ( H , I , n = 6 culture wells in two separate experiments). This was associated with an increased phospho-MOB1 level ( H and J ) and an increased P-YAP over total YAP ratio ( H and K ). Taken together, this suggests that MYOCD/SRF promotes the activity of Hippo via phospho-MOB1 and LATS2 to suppress YAP/TAZ activity; consequently, deletion of SRF in the aorta is expected to release YAP/TAZ from a critical inhibitory influence from Hippo. As prior work demonstrated that YAP/TAZ are important upstream regulators of MYOCD, we propose that the effect of MYOCD/SRF on Hippo represents an inhibitory and homeostatic feedback loop as depicted schematically in L. Lats2, large tumor suppressor kinase 2; MYOCD, myocardin; SMC, smooth muscle cell; SRF, serum response factor; TAZ, WW domain containing transcription regulator 1; YAP, Yes associated transcriptional regulator.
    Human Coronary Artery Smooth Muscle Cells (Smcs), supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+coronary+artery+smcs/human+coronary+artery+smooth+muscle+cells++hcasmcs++hereinafter+referred+to+as+vsmcs+/pm40081573-326-4-15
    Average 90 stars, based on 1 article reviews
    human coronary artery smooth muscle cells (smcs) - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    90
    Lonza human coronary artery smooth muscle cells (smc)
    MYOCD/SRF remodels Hippo. To understand YAP/TAZ activation in i8-SRF-KO aorta, we overlapped YAP/TAZ regulators (171 proteins) from a recent review with the differentially expressed proteins in i8-SRF-KO versus control aorta (729 proteins) to identify an overlap of 27 proteins ( A ). YAP/TAZ activators that were increased and inhibitors that were reduced (i8-SRF-KO vs. Ctrl) were highlighted with their respective protein names in black. Subsequently, 11 out of 27 changes were expected to activate YAP/TAZ whereas the remainder were expected to inhibit YAP/TAZ. Because core Hippo kinases were not recovered in our mass spectroscopy experiment, we next overlapped core Hippo constituents with a previous RNA-seq experiment (n = 4 experiments were cell were treated with either Ad-CMV-null or Ad-CMV-MYOCD) where MYOCD was overexpressed, uncovering significant increases of MOB1A , LATS1 , and LATS2 ( B ). Moreover, both SRF and MYOCD correlated with LATS2 at the mRNA level across human arteries ( C ). We therefore hypothesized that MYOCD/SRF may control the LATS2 protein level. Western blotting using lysates from control and i8-SRF-KO aortae revealed reduction of a major Lats2 band migrating at 240 kDa ( D , summarized data in E , n = 6 mice in each group) following SRF depletion. Lats1 ( D ), and Slmap (major isoform at 40 kDa, D ), included to allow for comparison with the mass spectroscopy in A , were not significantly reduced ( D and F ). HSP90, H3, and proteins remaining on the gel after transfer were included as loading controls. A Lats2 band migrating at 240 kDa, essentially eliminated by a LATS2-targeted siRNA (siLATS2c), was also detected in cultured smooth muscle cells from the <t>human</t> <t>coronary</t> artery following MYOCD transduction ( G , n = 3 culture wells). In a larger experiment, overexpression of MYOCD in human <t>SMCs</t> increased LATS2 >50-fold ( H , I , n = 6 culture wells in two separate experiments). This was associated with an increased phospho-MOB1 level ( H and J ) and an increased P-YAP over total YAP ratio ( H and K ). Taken together, this suggests that MYOCD/SRF promotes the activity of Hippo via phospho-MOB1 and LATS2 to suppress YAP/TAZ activity; consequently, deletion of SRF in the aorta is expected to release YAP/TAZ from a critical inhibitory influence from Hippo. As prior work demonstrated that YAP/TAZ are important upstream regulators of MYOCD, we propose that the effect of MYOCD/SRF on Hippo represents an inhibitory and homeostatic feedback loop as depicted schematically in L. Lats2, large tumor suppressor kinase 2; MYOCD, myocardin; SMC, smooth muscle cell; SRF, serum response factor; TAZ, WW domain containing transcription regulator 1; YAP, Yes associated transcriptional regulator.
    Human Coronary Artery Smooth Muscle Cells (Smc), supplied by Lonza, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+coronary+artery+smcs/human+coronary+artery+smooth+muscle+cells/pmc11444369__cir___150___1101___s001-100-23-30
    Average 90 stars, based on 1 article reviews
    human coronary artery smooth muscle cells (smc) - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    92
    Cell Applications Inc human aca smc
    MYOCD/SRF remodels Hippo. To understand YAP/TAZ activation in i8-SRF-KO aorta, we overlapped YAP/TAZ regulators (171 proteins) from a recent review with the differentially expressed proteins in i8-SRF-KO versus control aorta (729 proteins) to identify an overlap of 27 proteins ( A ). YAP/TAZ activators that were increased and inhibitors that were reduced (i8-SRF-KO vs. Ctrl) were highlighted with their respective protein names in black. Subsequently, 11 out of 27 changes were expected to activate YAP/TAZ whereas the remainder were expected to inhibit YAP/TAZ. Because core Hippo kinases were not recovered in our mass spectroscopy experiment, we next overlapped core Hippo constituents with a previous RNA-seq experiment (n = 4 experiments were cell were treated with either Ad-CMV-null or Ad-CMV-MYOCD) where MYOCD was overexpressed, uncovering significant increases of MOB1A , LATS1 , and LATS2 ( B ). Moreover, both SRF and MYOCD correlated with LATS2 at the mRNA level across human arteries ( C ). We therefore hypothesized that MYOCD/SRF may control the LATS2 protein level. Western blotting using lysates from control and i8-SRF-KO aortae revealed reduction of a major Lats2 band migrating at 240 kDa ( D , summarized data in E , n = 6 mice in each group) following SRF depletion. Lats1 ( D ), and Slmap (major isoform at 40 kDa, D ), included to allow for comparison with the mass spectroscopy in A , were not significantly reduced ( D and F ). HSP90, H3, and proteins remaining on the gel after transfer were included as loading controls. A Lats2 band migrating at 240 kDa, essentially eliminated by a LATS2-targeted siRNA (siLATS2c), was also detected in cultured smooth muscle cells from the <t>human</t> <t>coronary</t> artery following MYOCD transduction ( G , n = 3 culture wells). In a larger experiment, overexpression of MYOCD in human <t>SMCs</t> increased LATS2 >50-fold ( H , I , n = 6 culture wells in two separate experiments). This was associated with an increased phospho-MOB1 level ( H and J ) and an increased P-YAP over total YAP ratio ( H and K ). Taken together, this suggests that MYOCD/SRF promotes the activity of Hippo via phospho-MOB1 and LATS2 to suppress YAP/TAZ activity; consequently, deletion of SRF in the aorta is expected to release YAP/TAZ from a critical inhibitory influence from Hippo. As prior work demonstrated that YAP/TAZ are important upstream regulators of MYOCD, we propose that the effect of MYOCD/SRF on Hippo represents an inhibitory and homeostatic feedback loop as depicted schematically in L. Lats2, large tumor suppressor kinase 2; MYOCD, myocardin; SMC, smooth muscle cell; SRF, serum response factor; TAZ, WW domain containing transcription regulator 1; YAP, Yes associated transcriptional regulator.
    Human Aca Smc, supplied by Cell Applications Inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+coronary+artery+smcs/Human+Coronary+Artery+Smooth+Muscle+Cells%3A+Plaque%3A+HCASMC-q/pm38982274-36-3-27
    Average 92 stars, based on 1 article reviews
    human aca smc - by Bioz Stars, 2026-09
    92/100 stars
      Buy from Supplier

    Image Search Results


    MYOCD/SRF remodels Hippo. To understand YAP/TAZ activation in i8-SRF-KO aorta, we overlapped YAP/TAZ regulators (171 proteins) from a recent review with the differentially expressed proteins in i8-SRF-KO versus control aorta (729 proteins) to identify an overlap of 27 proteins ( A ). YAP/TAZ activators that were increased and inhibitors that were reduced (i8-SRF-KO vs. Ctrl) were highlighted with their respective protein names in black. Subsequently, 11 out of 27 changes were expected to activate YAP/TAZ whereas the remainder were expected to inhibit YAP/TAZ. Because core Hippo kinases were not recovered in our mass spectroscopy experiment, we next overlapped core Hippo constituents with a previous RNA-seq experiment (n = 4 experiments were cell were treated with either Ad-CMV-null or Ad-CMV-MYOCD) where MYOCD was overexpressed, uncovering significant increases of MOB1A , LATS1 , and LATS2 ( B ). Moreover, both SRF and MYOCD correlated with LATS2 at the mRNA level across human arteries ( C ). We therefore hypothesized that MYOCD/SRF may control the LATS2 protein level. Western blotting using lysates from control and i8-SRF-KO aortae revealed reduction of a major Lats2 band migrating at 240 kDa ( D , summarized data in E , n = 6 mice in each group) following SRF depletion. Lats1 ( D ), and Slmap (major isoform at 40 kDa, D ), included to allow for comparison with the mass spectroscopy in A , were not significantly reduced ( D and F ). HSP90, H3, and proteins remaining on the gel after transfer were included as loading controls. A Lats2 band migrating at 240 kDa, essentially eliminated by a LATS2-targeted siRNA (siLATS2c), was also detected in cultured smooth muscle cells from the human coronary artery following MYOCD transduction ( G , n = 3 culture wells). In a larger experiment, overexpression of MYOCD in human SMCs increased LATS2 >50-fold ( H , I , n = 6 culture wells in two separate experiments). This was associated with an increased phospho-MOB1 level ( H and J ) and an increased P-YAP over total YAP ratio ( H and K ). Taken together, this suggests that MYOCD/SRF promotes the activity of Hippo via phospho-MOB1 and LATS2 to suppress YAP/TAZ activity; consequently, deletion of SRF in the aorta is expected to release YAP/TAZ from a critical inhibitory influence from Hippo. As prior work demonstrated that YAP/TAZ are important upstream regulators of MYOCD, we propose that the effect of MYOCD/SRF on Hippo represents an inhibitory and homeostatic feedback loop as depicted schematically in L. Lats2, large tumor suppressor kinase 2; MYOCD, myocardin; SMC, smooth muscle cell; SRF, serum response factor; TAZ, WW domain containing transcription regulator 1; YAP, Yes associated transcriptional regulator.

    Journal: The Journal of Biological Chemistry

    Article Title: Declining activity of serum response factor in aging aorta in relation to aneurysm progression

    doi: 10.1016/j.jbc.2025.108400

    Figure Lengend Snippet: MYOCD/SRF remodels Hippo. To understand YAP/TAZ activation in i8-SRF-KO aorta, we overlapped YAP/TAZ regulators (171 proteins) from a recent review with the differentially expressed proteins in i8-SRF-KO versus control aorta (729 proteins) to identify an overlap of 27 proteins ( A ). YAP/TAZ activators that were increased and inhibitors that were reduced (i8-SRF-KO vs. Ctrl) were highlighted with their respective protein names in black. Subsequently, 11 out of 27 changes were expected to activate YAP/TAZ whereas the remainder were expected to inhibit YAP/TAZ. Because core Hippo kinases were not recovered in our mass spectroscopy experiment, we next overlapped core Hippo constituents with a previous RNA-seq experiment (n = 4 experiments were cell were treated with either Ad-CMV-null or Ad-CMV-MYOCD) where MYOCD was overexpressed, uncovering significant increases of MOB1A , LATS1 , and LATS2 ( B ). Moreover, both SRF and MYOCD correlated with LATS2 at the mRNA level across human arteries ( C ). We therefore hypothesized that MYOCD/SRF may control the LATS2 protein level. Western blotting using lysates from control and i8-SRF-KO aortae revealed reduction of a major Lats2 band migrating at 240 kDa ( D , summarized data in E , n = 6 mice in each group) following SRF depletion. Lats1 ( D ), and Slmap (major isoform at 40 kDa, D ), included to allow for comparison with the mass spectroscopy in A , were not significantly reduced ( D and F ). HSP90, H3, and proteins remaining on the gel after transfer were included as loading controls. A Lats2 band migrating at 240 kDa, essentially eliminated by a LATS2-targeted siRNA (siLATS2c), was also detected in cultured smooth muscle cells from the human coronary artery following MYOCD transduction ( G , n = 3 culture wells). In a larger experiment, overexpression of MYOCD in human SMCs increased LATS2 >50-fold ( H , I , n = 6 culture wells in two separate experiments). This was associated with an increased phospho-MOB1 level ( H and J ) and an increased P-YAP over total YAP ratio ( H and K ). Taken together, this suggests that MYOCD/SRF promotes the activity of Hippo via phospho-MOB1 and LATS2 to suppress YAP/TAZ activity; consequently, deletion of SRF in the aorta is expected to release YAP/TAZ from a critical inhibitory influence from Hippo. As prior work demonstrated that YAP/TAZ are important upstream regulators of MYOCD, we propose that the effect of MYOCD/SRF on Hippo represents an inhibitory and homeostatic feedback loop as depicted schematically in L. Lats2, large tumor suppressor kinase 2; MYOCD, myocardin; SMC, smooth muscle cell; SRF, serum response factor; TAZ, WW domain containing transcription regulator 1; YAP, Yes associated transcriptional regulator.

    Article Snippet: Human coronary artery SMCs were obtained from Thermo Fisher Scientific (C-017-5C, Gibco) and cultured in Human Vascular Smooth Muscle Cell Basal Medium (M231500, Thermo Fisher Scientific) supplemented with 5% smooth muscle growth supplement (S00725) and PEST (50 U/ml penicillin and 50 μg/ml streptomycin, Biochrom, A 2212).

    Techniques: Activation Assay, Control, Mass Spectrometry, RNA Sequencing, Western Blot, Comparison, Cell Culture, Transduction, Over Expression, Activity Assay